Lonza Group , the Switzerland-based maker of drug ingredients, plummeted 25 per cent yesterday after comments from its chief executive indicated a worse- than-expected outlook for the sector.
Lonza announced yesterday that operating profit would be between SFr360m-SFr380m in 2009, compared to SFr441m ($433m) a year earlier.
